TICKERNERD
Menu
CARLCARLHealthcare · Health Information Services

CARL Stock Forecast: Carlsmed, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$16
−2.73% on the day

The 5 Wall Street analysts covering Carlsmed, Inc. hold a median 12-month price target of $18 — +12.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$438.2M
Ticker Nerd rank
22 / 100
Median analyst target
$18
Analysts covering
5
Total return, dividends reinvested
1W
+12.1%
1M
+39.6%
YTD
+30.0%
1Y
+24.6%
From 52W high
−5.5%
From 52W low
+81.8%
$9
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CARL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Carlsmed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
22 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
79
Size
56
Growth
38
Quality
34
Issuance
28
Value
26
Momentum
24
Accruals
23
Volatility
11

Revisions (79): Analysts have, on balance, been raising their forecasts.

Volatility (11): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CARL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CARL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20Oct 25Jan 26Apr 26Jul 26CARLHigh $23Median $18Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $17Median $18High $23

The green dot is the last close — the median target sits +12.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Aug 2026Truist SecuritiesMaintainsBuy$18 → $20
1 July 2026NeedhamInitiatesBuy—
1 July 2026NeedhamInitiatesBuy$17
6 May 2026BTIGReiteratesBuy—
15 Apr 2026Truist SecuritiesMaintainsBuy—
9 Apr 2026Goldman SachsMaintainsBuy—
15 Dec 2025BTIGReiteratesBuy—
7 Nov 2025BTIGMaintainsBuy—
7 Nov 2025Truist SecuritiesReiteratesBuy—
18 Aug 2025Goldman SachsInitiatesBuy—
18 Aug 2025Piper SandlerInitiatesOverweight—
18 Aug 2025Truist SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CARL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CARL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Carlsmed, Inc. (CARL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.6×

Cheaper than 92% of US stocks

Price / sales
6.9×

Cheaper than 18% of US stocks

Price / book
5.2×

Cheaper than 20% of US stocks

EV / EBITDA
−9.7×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
56.7%

Higher than 88% of US stocks

Earnings growth (YoY)
56.7%

Higher than 77% of US stocks

Gross margin
76.8%

Higher than 89% of US stocks

Operating margin
−58.3%

Higher than 16% of US stocks

Net margin
−57.4%

Higher than 9% of US stocks

Returns & dividend
Return on equity
−66.1%

Higher than 18% of US stocks

Return on assets
−28.2%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CARL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
CARLCarlsmed, Inc.$438.2M
22
NRCNRC Health$500.1M
87
SLPSimulations Plus, Inc.$372.1M
91
EVHEvolent Health, Inc.$529.2M
63
WEAVWeave Communications, Inc.$583.2M
79
CTEVClaritev Corp.$614.0M
64
SOPHSOPHiA GENETICS SA$712.0M
50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Carlsmed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CARL news & analysis

Carlsmed Eyes Growth as Cervical Launch, Medicare Shift Boost Spine Platform

MarketBeat · 13 Aug 2026positive

Carlsmed presented its growth strategy for its personalized spine-surgery platform at a Bank of America virtual event, citing clinical data, reimbursement changes, and a planned cervical product launch as key drivers.

Why it matters — The company's focus on a cervical launch and favorable Medicare shifts suggests potential expansion opportunities for CARL's platform beyond its current applications.

Carlsmed, Inc. (CARL) Presents at Bank of America SMID Cap Virtual Conference Transcript

Seeking Alpha · 12 Aug 2026neutral

Carlsmed, Inc. (CARL) presented at the Bank of America SMID Cap Virtual Conference, with a transcript of its presentation published on Seeking Alpha. The item reports the company's participation in the investor conference.

Why it matters — A CARL watcher would care because management's conference presentation offers an opportunity to hear the company's latest update to investors.

Carlsmed, Inc. (CARL) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Carlsmed, Inc. held its Q2 2026 earnings conference call. A transcript of the call was published on Seeking Alpha.

Why it matters — The earnings call transcript provides investors and analysts with detailed financial results and management commentary for the quarter.

Carlsmed Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

Carlsmed reported second-quarter 2026 revenue of $18.9 million, up 57% from $12.1 million a year earlier. Growth came from its aprevo lumbar platform and contributions from its newer cervical offering, which lifted procedure volumes.

Why it matters — The 57% revenue increase shows accelerating adoption across Carlsmed's lumbar and cervical product lines, a key indicator for investors tracking the company's commercial momentum.

Carlsmed, Inc. (CARL) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 5 Aug 2026positive

Carlsmed, Inc. reported a Q2 loss of $0.39 per share, which was narrower than the Zacks Consensus Estimate of a $0.40 loss and well below the $1.47 per-share loss it recorded a year earlier. The company also beat revenue estimates for the quarter.

Why it matters — For CARL watchers, the narrower-than-expected quarterly loss and revenue beat mark an improvement over both analyst forecasts and the company's prior-year performance.

FAQ

Frequently asked questions about CARL stock

What is the CARL stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Carlsmed, Inc. have a median 12-month price target of $18, with estimates ranging from $17 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CARL stock a buy right now?

Of the 5 analysts covering Carlsmed, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Carlsmed, Inc. 22 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CARL?

As at 22 Aug 2026, Carlsmed, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (79 of 100).

Will CARL stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +12.1% from the last close, and Ticker Nerd's factor model ranks Carlsmed, Inc. 22 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CARL stock forecast for 2030?

No analyst covering Carlsmed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CARL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $23 over the next 12 months.

How has CARL stock performed over the past year?

Carlsmed, Inc. returned +24.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Carlsmed, Inc. do?

Carlsmed, Inc. is a commercial-stage medical technology company founded in 2018 and headquartered in Carlsbad, California.

What is the latest news on CARL?

The most recent item we track (MarketBeat, 13 Aug 2026): "Carlsmed Eyes Growth as Cervical Launch, Medicare Shift Boost Spine Platform". Carlsmed presented its growth strategy for its personalized spine-surgery platform at a Bank of America virtual event, citing clinical data, reimbursement changes, and a planned cervical product launch as key drivers.

Company

About Carlsmed, Inc.

Carlsmed, Inc. is a commercial-stage medical technology company founded in 2018 and headquartered in Carlsbad, California. It specializes in AI-enabled personalized spine surgery solutions, aiming to enhance patient outcomes and reduce healthcare costs in spine fusion procedures. The company's core offering, the aprevo Technology Platform, integrates AI-powered software with custom-designed interbody implants tailored to each patient's unique vertebral bone topography and pathology, complemented by single-use surgical instruments. This comprehensive approach supports surgeons in traditional techniques by providing precise, patient-specific tools that set a new standard in spinal care. Operating within the health care equipment industry, Carlsmed, Inc. employs around 89 professionals and focuses on innovation at the intersection of artificial intelligence and orthopedic surgery. With a market capitalization reflecting its growth trajectory post its 2025 Nasdaq listing, the company plays a pivotal role in advancing precision medicine for complex spinal conditions, potentially transforming surgical efficiency and recovery times across global healthcare systems.

CEO Mr. Michael John Cordonnier · 127 employees · United States · https://carlsmed.com